查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2005128

急性細菌性皮膚和組織感染疾病市場：按產品類型、給藥途徑、最終用戶、分銷管道和治療方法分類－2026-2032年全球市場預測

Acute Bacterial Skin & Skin Structure Infection Market by Product Type, Route Of Administration, End User, Distribution Channel, Treatment Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，急性細菌性皮膚和皮膚結構感染疾病市場價值將達到 123.5 億美元，到 2026 年將成長至 135 億美元，到 2032 年將達到 226.2 億美元，複合年成長率為 9.02%。

主要市場統計數據
基準年 2025 123.5億美元
預計年份：2026年 135億美元
預測年份 2032 226.2億美元
複合年成長率 (%) 9.02%

簡要概述了臨床、商業性和政策因素對急性細菌性皮膚和皮膚結構感染疾病。

急性細菌性皮膚感染和結構性皮膚感染疾病呈現出複雜的臨床和商業性格局，受到病原體譜系演變、醫療服務環境變化以及監管力度加大的影響。以下概述梳理了當前情勢，整合了影響治療方法選擇和取得途徑的關鍵因素，並指出了製藥公司、醫療服務提供者和保險公司面臨的策略挑戰。透過聚焦臨床實際情況和市場動態，本分析為商業化、臨床開發以及融入醫療體係等方面的精準決策奠定了基礎。

抗生素抗藥性、向門診治療的轉變、診斷技術的整合以及基於價值的合約如何全面重塑治療方法的開發和商業化策略。

在急性細菌性皮膚及皮膚結構感染疾病領域，正在發生多項變革性變化，這些變化正在重新定義治療方法的研發、應用和報銷方式。首先，為應對抗生素抗藥性，臨床上對標靶藥物和合理用藥方案的投入不斷增加；同時，診斷試劑生產商和治療藥物研發商之間的合作也在加強，以推動基於細菌培養和PCR檢測的治療方法，從而減少頻譜抗生素的使用，並維持療效。

本檢驗了近期美國關稅調整對治療和診斷藥物整個供應鏈的韌性、籌資策略和商業性競爭的影響。

2025年美國關稅環境的變化為急性細菌性皮膚及皮膚結構感染疾病治療用藥品及相關產品的供應鏈、採購成本和策略採購帶來了新的考量。關稅政策的變化正在影響門診和居家照護中使用的進口藥品活性成分、無菌生產組件、診斷試劑盒和一次性醫療設備的成本基礎。依賴跨境供應鏈的企業正在採取措施降低關稅波動帶來的風險，例如重新評估貨源、將生產轉移到近岸地區以及與具有國內生產能力的契約製造製造商合作。

將產品屬性、給藥途徑、醫療保健環境、分銷管道和基於診斷的治療路徑與策略決策聯繫起來的詳細細分分析。

細分市場層面的洞察揭示了產品類型、給藥途徑、終端用戶環境、分銷管道和治療方法等方面的顯著趨勢，每種因素都對藥物的研發和商業化產生獨特的影響。根據產品類型，市場細分為品牌抗生素、非專利抗生素和新藥，其中非專利抗生素進一步細分為頭孢菌素類、林可醯胺類、大環內酯類和青黴素類。這凸顯了製定生命週期管理策略的必要性，以便在應對學名藥競爭的同時，保護新進入者的市場價值。

區域比較分析突顯了美洲、歐洲、中東、非洲和亞太地區在監管、報銷、供應鏈和臨床實踐因素方面的差異。

區域趨勢影響臨床實踐、法規環境和商業性准入，並對相關人員如何優先考慮投資和分配資源產生重大影響。在美洲，醫療保健系統優先考慮快速獲得有效的門診服務，並已實施影響藥物採用決策的藥物管理框架。私人和公共保險公司越來越要求提供真實世界療效和成本節約的證據，這迫使製造商投資於本地衛生經濟資料集和醫療服務提供者參與計畫。同時，供應鏈挑戰和關稅影響正在影響住院和門診管道的製造地選擇和採購政策。

成熟企業、專業研發公司、診斷藥物創新者和生產合作夥伴如何透過合作、證據生成和商業化的協同效應重建其競爭優勢。

此治療領域的競爭動態由多家成熟的大型製藥企業、中小型專科藥物研發公司、診斷服務提供者和契約製造組織（CMO）組成，它們各自為價值鏈貢獻著不同的優勢。大型成熟公司憑藉其龐大的商業基礎設施、大規模的臨床網路以及在應對複雜監管環境方面的豐富經驗，持續維護其自有品牌產品組合。同時，專科藥物研發公司則專注於差異化的作用機制、快速的研發週期以及針對特定適應症的治療，致力於解決抗藥性病原體和未被滿足的醫療需求。

為整合診斷、加強供應鏈、最佳化全通路存取以及與循證和基於價值的支付預期保持一致，提出切實可行的優先建議。

產業領導者應採取多管齊下的策略，將產品開發、臨床證據和商業性執行與不斷變化的醫療保健和政策環境相協調。首先，應優先考慮診斷整合，透過與實驗室和即時檢測公司建立夥伴關係，支持基於培養和PCR的治療路徑。及時、基於診斷的決策能夠增強對醫療服務提供者和支付方的價值提案。同時，應投資於真實世界數據（REW）項目，收集門診手術中心、家庭醫療保健機構和醫院的治療結果，以支持關於縮短住院時間、降低再入院率和提高患者滿意度的說法。

我們將透過整合策略挑戰，推動永續的醫療服務取得和臨床影響，並專注於以診斷技術為驅動的醫療保健、具韌性的供應鏈和實證商業策略。

總之，由於抗生素抗藥性、門診治療的普及、診斷技術的進步以及採購壓力的變化，急性細菌性皮膚及皮膚結構感染疾病領域正處於轉折點。這些因素為具有明確臨床差異的新型藥物以及診斷和治療手段的及時策略性組合創造了機遇，從而使治療決策能夠基於細菌培養和PCR檢測結果。同時，價格調整、供應鏈日益複雜以及醫保報銷預期凸顯了製定穩健的產業計畫和循證商業性策略的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：急性細菌性皮膚及皮膚組織感染疾病市場：依產品類型分類

  • 品牌抗生素
  • 非專利抗生素
    • 頭孢菌素
    • 林可醯胺
    • 大環內酯類
    • 青黴素
  • 新藥

第9章：急性細菌性皮膚及皮膚組織感染疾病市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 外用

第10章：急性細菌性皮膚及皮膚組織感染疾病市場：依最終使用者分類

  • 門診手術中心
  • 家庭醫療保健設施
  • 醫院

第11章：急性細菌性皮膚及皮膚組織感染疾病市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章：急性細菌性皮膚及皮膚組織感染疾病，依治療方法。

  • 經驗性治療
  • 標靶治療
    • 根據培養結果進行治療
    • 基於PCR的治療

第13章：急性細菌性皮膚及皮膚組織感染疾病市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：急性細菌性皮膚及皮膚組織感染疾病市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：急性細菌性皮膚及皮膚組織感染疾病市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國急性細菌性皮膚及感染疾病市場

第17章：中國急性細菌性皮膚及感染疾病市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc
  • Basilea Pharmaceutica Ltd
  • Bayer AG
  • Cipher Pharmaceuticals Inc
  • Cipla Limited
  • Cumberland Pharmaceuticals Inc
  • Dr. Reddy's Laboratories Ltd
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd
  • Lupin Limited
  • Melinta Therapeutics LLC
  • Menarini Group
  • Merck & Co. Inc
  • Nabriva Therapeutics plc
  • Novartis AG
  • Paratek Pharmaceuticals Inc
  • Pfizer Inc
  • Teva Pharmaceutical Industries Ltd
  • Viatris Inc
  • Zydus Lifesciences Limited
Product Code: MRR-B16853776E4F

The Acute Bacterial Skin & Skin Structure Infection Market was valued at USD 12.35 billion in 2025 and is projected to grow to USD 13.50 billion in 2026, with a CAGR of 9.02%, reaching USD 22.62 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 12.35 billion
Estimated Year [2026] USD 13.50 billion
Forecast Year [2032] USD 22.62 billion
CAGR (%) 9.02%

A concise orientation to the clinical, commercial, and policy drivers reshaping treatment pathways and strategic priorities in acute bacterial skin and skin structure infections

Acute bacterial skin and skin structure infections present a complex clinical and commercial landscape shaped by evolving pathogen profiles, shifting care settings, and heightened regulatory scrutiny. The introduction below frames the current environment, synthesizes key drivers influencing therapeutic selection and access, and clarifies the strategic stakes for manufacturers, providers, and payers. By centering on clinical realities and market dynamics, this analysis establishes the foundation for targeted decision making across commercialization, clinical development, and health system integration.

Clinically, the incidence and diversity of causative organisms have driven renewed attention to rapid diagnostics, antibiotic stewardship, and novel therapeutic approaches that balance efficacy with resistance mitigation. Concurrently, care delivery has migrated in part from inpatient wards to ambulatory surgical centers and home healthcare settings, influencing formulary decisions, administration routes, and the relative importance of oral versus intravenous options. These shifts underscore the need for adaptable commercial strategies that align product attributes with end-user workflows and procurement mechanisms.

From a regulatory and reimbursement standpoint, stakeholders face increasing pressure to demonstrate value in the form of improved outcomes, reduced hospital stays, and lower overall costs of care. This pressure amplifies the importance of differentiated clinical evidence, real-world performance data, and clear positioning against existing branded and generic antibiotics. The ensuing sections build on this introduction to outline transformative market shifts, tariff impacts, segmentation intelligence, regional nuances, competitive positioning, actionable recommendations, and the methodology underpinning the analysis.

How antimicrobial resistance, care migration to outpatient settings, diagnostics integration, and value based contracting are collectively reshaping therapeutic development and commercialization strategies

The landscape for acute bacterial skin and skin structure infections is undergoing several transformative shifts that will redefine how therapies are developed, delivered, and reimbursed. First, the clinical imperative to counteract antimicrobial resistance has intensified investment in targeted agents and stewardship programs, prompting greater collaboration between diagnostics firms and therapeutics developers to enable culture guided and PCR guided treatment approaches that reduce broad-spectrum exposure and preserve efficacy.

Concurrently, care delivery is transitioning toward outpatient and home-based models, elevating the importance of route of administration in commercial planning. Intravenous options maintain a role for severe presentations, but oral and topical formulations are gaining prominence for their potential to shorten hospital stays and support ambulatory care pathways. This reorientation affects procurement channels and necessitates engagement with hospital pharmacies, retail and online pharmacies, and home healthcare providers to ensure seamless access.

Economically and operationally, payers are increasingly focused on value-based contracting and outcomes-based reimbursement, incentivizing manufacturers to demonstrate tangible reductions in length of stay, readmissions, and overall treatment costs. In parallel, regulatory frameworks are emphasizing accelerated development pathways for novel agents that address unmet needs, while also requiring robust post-marketing surveillance. Taken together, these shifts demand cross-functional strategies that integrate clinical evidence generation, diagnostics partnerships, and agile commercial models to capture emerging opportunities.

Examining how recent United States tariff adjustments influence supply chain resilience, sourcing strategies, and commercial competitiveness across therapeutics and diagnostics supply chains

The evolving tariff environment of the United States in 2025 has introduced new considerations for the supply chain, procurement costs, and strategic sourcing for therapeutics and ancillary products relevant to treatment of acute bacterial skin and skin structure infections. Tariff policy changes have influenced the cost base for imported active pharmaceutical ingredients, sterile manufacturing components, diagnostic kits, and single-use devices used in outpatient and home-care administration. Companies that rely on cross-border supply chains have responded by reassessing origins of supply, nearshoring production, and engaging contract manufacturers with domestic capabilities to mitigate exposure to tariff volatility.

In response, firms have prioritized supply chain resilience through diversified sourcing strategies and strengthened supplier agreements that include contingency planning for tariff-related disruptions. These measures have implications for pricing negotiations, procurement cycles in hospital pharmacies and retail channels, and the relative competitiveness of certain product types, particularly those for which manufacturing complexity or raw material sourcing is concentrated in specific geographies. Diagnostics manufacturers and distributors have likewise adapted their channel strategies to preserve access to culture and PCR guided testing modalities amid shifting import costs.

Although tariffs influence cost structures, they also catalyze strategic investments in local manufacturing capacity and vertically integrated models that can buffer commercial programs from policy shifts. As a result, stakeholders are balancing near-term operational adaptations with longer-term capital planning aimed at securing supply continuity, protecting margin, and maintaining timely patient access to both therapeutics and diagnostics across inpatient and outpatient settings.

Detailed segmentation intelligence that aligns product attributes, administration routes, care settings, distribution channels, and diagnostics driven treatment pathways to strategic decision making

Segment-level insights reveal differentiated dynamics across product types, administration routes, end-user settings, distribution channels, and treatment approaches, each carrying distinct implications for development and commercialization. Based on Product Type, market is studied across Branded Antibiotics, Generic Antibiotics, and Novel Agents, with Generic Antibiotics further studied across Cephalosporins, Lincosamides, Macrolides, and Penicillins, which underscores the need for lifecycle management strategies that address generic competition while protecting niche value for novel entrants.

Based on Route Of Administration, market is studied across Intravenous, Oral, and Topical, and the choice among these influences clinical adoption, patient preference, and administration costs; oral agents and topical formulations increasingly serve as enablers for outpatient transition, while intravenous therapies remain essential for severe infections. Based on End User, market is studied across Ambulatory Surgical Centers, Home Healthcare Settings, and Hospitals, emphasizing that engagement strategies must adapt to procurement behaviors, clinical workflows, and reimbursement profiles unique to each setting.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies, which highlights the growing importance of omnichannel access and digital fulfillment for outpatient regimens. Finally, Based on Treatment Type, market is studied across Empiric Treatment and Targeted Treatment, with Targeted Treatment further studied across Culture Guided and Pcr Guided approaches; this segmentation points to a bifurcation between broad empiric therapies and precision-driven strategies that leverage diagnostics to optimize outcomes. Together, these segment lenses enable stakeholders to align product development, evidence generation, and channel strategies with clinical realities and procurement behaviors.

Comparative regional analysis highlighting distinct regulatory, reimbursement, supply chain, and clinical practice drivers across the Americas, Europe Middle East and Africa, and Asia Pacific

Regional dynamics shape clinical practice, regulatory environments, and commercial access in ways that materially affect how stakeholders prioritize investments and allocate resources. In the Americas, health systems emphasize rapid access to effective outpatient therapies and have implemented stewardship frameworks that influence formulary decisions; private and public payers increasingly demand evidence of real-world outcomes and cost offsets, prompting manufacturers to invest in local health economics datasets and provider engagement programs. Meanwhile, supply chain considerations and tariff impacts influence manufacturing footprint decisions and procurement preferences across both inpatient and outpatient channels.

In Europe, Middle East & Africa, heterogeneity in regulatory pathways, reimbursement models, and clinical practice patterns requires tailored market entry strategies. Many countries in this region maintain robust stewardship programs alongside national procurement mechanisms, which can favor therapeutics and diagnostics that demonstrate clear comparative effectiveness and cost containment. Emerging economies within the region are expanding access to outpatient care and home health services, creating opportunities for oral and topical therapies, while also presenting logistical challenges related to cold chain and distribution.

The Asia-Pacific region presents a mix of high-volume markets with rapid adoption of novel diagnostics and digital health tools, alongside jurisdictions with distinct regulatory timelines and pricing pressures. Investments in local clinical research and manufacturing capacity are common, and partnerships with regional distributors or contract manufacturers often accelerate market access. Across all regions, stakeholders should prioritize localized evidence generation, payer engagement, and supply chain strategies that reflect regional policy, clinical practice, and procurement realities to ensure sustainable access and adoption.

How incumbents, specialty developers, diagnostics innovators, and manufacturing partners are reshaping competitive advantages through collaboration, evidence generation, and commercialization synergies

Competitive dynamics in this therapeutic area reflect a mix of established large pharmaceutical firms, smaller specialty developers, diagnostics providers, and contract manufacturing organizations, each contributing different strengths to the value chain. Large incumbent companies continue to leverage broad commercial infrastructures, extensive clinical networks, and experience navigating complex regulatory landscapes to sustain branded product portfolios, whereas specialty developers focus on differentiated mechanisms of action, rapid development cycles, and targeted niche indications to address resistant pathogens and unmet clinical needs.

Diagnostic companies and clinical laboratories have become strategic partners in enabling targeted treatment approaches; their ability to deliver timely culture guided and PCR guided results directly affects prescribing behavior and the commercial trajectory of associated therapeutics. Contract development and manufacturing organizations play an increasingly critical role in scaling production for injectable therapies and in supporting formulation transitions from intravenous to more patient-friendly routes of administration.

Strategic alliances, licensing deals, and co-promotion agreements are prevalent as companies seek to combine strengths in discovery, development, and market access. Across the competitive landscape, differentiation now hinges on robust real-world evidence, integrated diagnostic solutions, and value-based contracting capabilities. For organizations planning entry or expansion, aligning clinical differentiation with pragmatic commercialization plans and diagnostic partnerships will be essential to secure preferential positioning among providers and payers.

Practical and prioritized recommendations for integrating diagnostics, strengthening supply chains, optimizing omnichannel access, and aligning evidence generation with value based payment expectations

Industry leaders should adopt a multi-pronged strategy that aligns product development, clinical evidence, and commercial execution to the changing care and policy environment. First, prioritize diagnostics integration by establishing partnerships with laboratories and point-of-care testing firms to support culture guided and PCR guided treatment pathways; demonstrating timely diagnostic-driven decision making will strengthen value propositions with providers and payers. Concurrently, invest in real-world evidence programs that capture outcomes across Ambulatory Surgical Centers, Home Healthcare Settings, and Hospitals to substantiate claims about reduced length of stay, lower readmissions, and improved patient satisfaction.

Second, adapt commercialization models to omnichannel distribution frameworks that include hospital pharmacies, online pharmacies, and retail pharmacies while ensuring seamless fulfillment and patient support services for oral and topical therapies. Consider flexible pricing and value-based contracting arrangements that align reimbursement with measurable patient outcomes. Third, enhance supply chain resilience by diversifying suppliers of active pharmaceutical ingredients and considering nearshoring or regional manufacturing partnerships to mitigate tariff exposure and logistical risk.

Finally, integrate lifecycle management tactics that manage generic competition within Cephalosporins, Lincosamides, Macrolides, and Penicillins while protecting the commercial potential of novel agents through targeted clinical differentiation, post-marketing surveillance, and proactive stakeholder engagement. By orchestrating these initiatives, organizations can drive adoption, protect margin, and demonstrate continuous value to payers, providers, and patients.

The research underpinning this analysis employed a mixed-methods approach designed to triangulate clinical, commercial, and policy inputs to produce actionable insights. Primary research included structured interviews with clinicians across hospital, ambulatory, and home healthcare settings, procurement and formulary decision-makers, diagnostics laboratory directors, and senior commercial executives from developers and distributors. These conversations provided qualitative depth on prescribing behavior, treatment pathways, and procurement criteria, and were complemented by targeted expert panels to validate emerging trends and scenario implications.

Secondary research integrated peer-reviewed clinical literature, regulatory guidance documents, product labels, and published clinical trial results to ground therapeutic and diagnostic assessments in evidence. Industry databases and public filings were examined to map product pipelines, approval timelines, and patent landscapes where available. Data triangulation was applied to reconcile differences across sources, and sensitivity checks were performed to ensure conclusions remained robust under alternative assumptions about care setting adoption and supply chain responses.

Finally, analytical frameworks were used to synthesize findings into strategic implications and recommendations. These frameworks emphasized alignment across clinical differentiation, diagnostics enabling targeted treatment, channel strategy, and regional access planning, ensuring that the conclusions are actionable for developers, payers, and health systems seeking to navigate the evolving acute bacterial skin and skin structure infection environment.

A synthesis of strategic imperatives emphasizing diagnostics enabled care, resilient supply chains, and evidence based commercial strategies to drive sustainable access and clinical impact

In conclusion, the acute bacterial skin and skin structure infection arena is at an inflection point driven by antimicrobial resistance, shifts to outpatient care, diagnostic advances, and evolving procurement pressures. These forces are creating opportunities for novel agents that offer clear clinical differentiation and for strategic combinations of therapeutics with timely diagnostics that enable culture guided and PCR guided treatment decisions. At the same time, tariff developments, supply chain complexities, and reimbursement expectations underscore the need for resilient operational planning and evidence-centered commercial approaches.

Stakeholders that succeed will be those that integrate clinical evidence generation with pragmatic commercialization strategies-aligning product attributes to route of administration preferences, end-user workflows across Ambulatory Surgical Centers, Home Healthcare Settings, and Hospitals, and distribution pathways spanning Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. By investing in diagnostics partnerships, real-world evidence, and flexible supply chain models, organizations can accelerate adoption, defend margins, and contribute meaningfully to improved patient outcomes. The pathway forward requires coordination across R&D, commercial, regulatory, and supply chain functions to turn insights into measurable impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Acute Bacterial Skin & Skin Structure Infection Market, by Product Type

  • 8.1. Branded Antibiotics
  • 8.2. Generic Antibiotics
    • 8.2.1. Cephalosporins
    • 8.2.2. Lincosamides
    • 8.2.3. Macrolides
    • 8.2.4. Penicillins
  • 8.3. Novel Agents

9. Acute Bacterial Skin & Skin Structure Infection Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Topical

10. Acute Bacterial Skin & Skin Structure Infection Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Home Healthcare Settings
  • 10.3. Hospitals

11. Acute Bacterial Skin & Skin Structure Infection Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Acute Bacterial Skin & Skin Structure Infection Market, by Treatment Type

  • 12.1. Empiric Treatment
  • 12.2. Targeted Treatment
    • 12.2.1. Culture Guided
    • 12.2.2. Pcr Guided

13. Acute Bacterial Skin & Skin Structure Infection Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Acute Bacterial Skin & Skin Structure Infection Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Acute Bacterial Skin & Skin Structure Infection Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Acute Bacterial Skin & Skin Structure Infection Market

17. China Acute Bacterial Skin & Skin Structure Infection Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc
  • 18.6. Basilea Pharmaceutica Ltd
  • 18.7. Bayer AG
  • 18.8. Cipher Pharmaceuticals Inc
  • 18.9. Cipla Limited
  • 18.10. Cumberland Pharmaceuticals Inc
  • 18.11. Dr. Reddy's Laboratories Ltd
  • 18.12. GlaxoSmithKline plc
  • 18.13. Glenmark Pharmaceuticals Ltd
  • 18.14. Lupin Limited
  • 18.15. Melinta Therapeutics LLC
  • 18.16. Menarini Group
  • 18.17. Merck & Co. Inc
  • 18.18. Nabriva Therapeutics plc
  • 18.19. Novartis AG
  • 18.20. Paratek Pharmaceuticals Inc
  • 18.21. Pfizer Inc
  • 18.22. Teva Pharmaceutical Industries Ltd
  • 18.23. Viatris Inc
  • 18.24. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY BRANDED ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY BRANDED ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY BRANDED ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY LINCOSAMIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY LINCOSAMIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY LINCOSAMIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PENICILLINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY NOVEL AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY NOVEL AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY NOVEL AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY EMPIRIC TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY EMPIRIC TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY EMPIRIC TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CULTURE GUIDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CULTURE GUIDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CULTURE GUIDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PCR GUIDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PCR GUIDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PCR GUIDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 143. GCC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GCC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. GCC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 146. GCC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. GCC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. GCC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. GCC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. GCC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 167. G7 ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. G7 ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. G7 ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 170. G7 ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. G7 ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. G7 ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. G7 ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. G7 ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 175. NATO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. NATO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. NATO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 178. NATO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. NATO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. NATO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. NATO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. NATO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, 2018-2032 (USD MILLION)